Drug Type Small molecule drug |
Synonyms MAK 683 |
Target |
Mechanism EED inhibitors(Polycomb protein EED inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H17FN6O |
InChIKeyXLIBABIFOBYHSV-UHFFFAOYSA-N |
CAS Registry1951408-58-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 2 | CN | 31 Aug 2020 | |
Ovarian Cancer | Phase 2 | CN | 31 Aug 2020 | |
Advanced cancer | Phase 2 | US | 03 Oct 2016 | |
Advanced cancer | Phase 2 | US | 03 Oct 2016 | |
Advanced cancer | Phase 2 | JP | 03 Oct 2016 | |
Advanced cancer | Phase 2 | JP | 03 Oct 2016 | |
Advanced cancer | Phase 2 | CA | 03 Oct 2016 | |
Advanced cancer | Phase 2 | CA | 03 Oct 2016 | |
Advanced cancer | Phase 2 | FR | 03 Oct 2016 | |
Advanced cancer | Phase 2 | FR | 03 Oct 2016 |
Phase 1 | 125 | lcgebmsnjp(qwlvppamey) = pbvjpsdiiz xeubcqsawg (toaedpwocs ) | - | 02 Jun 2022 | |||
lcgebmsnjp(qwlvppamey) = tjhscxkipl xeubcqsawg (toaedpwocs ) |